Dyspepsia News and Research

RSS

Indigestion, known as ''upset stomach'' or ''dyspepsia'', meaning hard or difficult digestion, is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. It can be accompanied by bloating, belching, nausea, or heartburn.

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.

24 Apr 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Unusual case of upper obstructive syndrome

Aorto-duodenal fistulae (ADF) are the most frequent aorto-enteric fistulae (80%) and the most frequent presenting sign of ADF is upper gastrointestinal bleeding (UGI).

25 Feb 2008

Experts say far too much is spent on needless indigestion drugs

According to two experts in Britain the National Health Service (NHS) is needlessly spending at least 100m pounds per year on indigestion drugs.

7 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Gastrointestinal disorders and work-related absenteeism

Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.

16 Oct 2007

Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction

As many as one in four people in westernized countries experience pain or discomfort in their upper abdomen, and physicians have almost nothing to offer except anti-acid medicines, which usually don't work.

20 Sep 2007

Genzyme announces results of clinical trials of Renvela and Renagel

Genzyme Corp. has announced the results of two new studies comparing a powder form of Renvela (sevelamer carbonate) to Renagel tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times per day, and one in which it was administered once per day.

19 Jun 2007

FDA approves Exelon to treat dementia of Parkinson's disease

FDA approves Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associated with Parkinson's disease.

27 Jun 2006

Drug combo significantly more effective in reducing dyspepsia in arthritis patients

UCLA/VA researchers found that for arthritis patients, taking a combination of two drugs may be most effective in protecting against stomach upset called dyspepsia, which is a side effect of common pain medications.

3 May 2006

Which herbs and dietary supplements can help children with nausea, constipation and similar gastrointestinal problems?

As more parents choose home remedies for their children's gastrointestinal complaints, the question arises, which ones really work?

30 Aug 2005

Chronic users NSAIDs have greater risk of bleeding and visible damage to their small intestine

According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) have an increased risk of bleeding and visible damage to their small intestine.

4 Jan 2005

Pfizer submits regulatory filings for Revatio (sildenafil citrate) as a treatment for pulmonary arterial hypertension

Sildenafil is the active ingredient in Viagra, Pfizer's erectile dysfunction medication used by more than 23 million men worldwide.

4 Dec 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

Study shows Levitra enhances patients' self-esteem by improving erections

The first clinical study to evaluate LEVITRA™ (vardenafil HCl) in men with mild Major Depressive Disorder (MDD) and erectile dysfunction (ED) showed LEVITRA produced statistically significant improvements over baseline in all measures of erectile function (EF) and depression/self-esteem. In the study, men taking Levitra were nearly three times more likely to report improved erections than men taking placebo.

24 Mar 2004